Amantadine Related Published Studies
Well-designed clinical trials related to Amantadine
Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. [2009.07]
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. [2008.11]
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. [2008.06.19]
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. [2007.08]
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study. [2007.07.28]
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. [2007.05]
Effect of early administration of the N-methyl-d-aspartate receptor antagonist amantadine on the development of postmastectomy pain syndrome: a prospective pilot study. [2007.03]
Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. [2007.02]
Modulation of human motor cortex excitability by single doses of amantadine. [2006.12]
Effect of Early Administration of the N-Methyl-D-Aspartate Receptor Antagonist Amantadine on the Development of Postmastectomy Pain Syndrome: A Prospective Pilot Study. [2006.09.20]
Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. [2006.05]
Effect of amantadine in essential tremor: a randomized, placebo-controlled trial. [2006.04]
Amantadine sulfate reduces experimental sensitization and pain in chronic back pain patients. [2006.03]
Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). [2006.03]
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. [2006.02]
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. [2006.01]
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. [2005.11]
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. [2005.11]
Placebo-controlled trial of amantadine in multiple-system atrophy. [2005.09]
Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report. [2005.09]
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. [2005.09]
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. [2005.05]
Effect of amantadine on motor memory consolidation in humans. [2005.03]
Amantadine for weight gain associated with olanzapine treatment. [2005.01]
Well-designed clinical trials possibly related to Amantadine
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. [2009.07.24]
Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. [2009.07]
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. [2009.07]
Efficacy and safety of memantine in Lewy body dementia. [2009.07]
Randomized controlled trial of memantine in dementia associated with Parkinson's disease. [2009.06.15]
The effects of memantine on prepulse inhibition. [2009.06]
Memantine induces reversible neurologic impairment in patients with MS. [2009.05.12]
Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. [2009.05]
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. [2009.04]
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. [2009.03.28]
Memantine for prophylaxis of chronic tension-type headache--a double-blind, randomized, crossover clinical trial. [2009.03]
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. [2008.12]
Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy. [2008.10.15]
Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. [2008.10.03]
[Observation on therapeutic effect of low energy He-Ne laser acupoint radiation on infantile cold] [2008.09]
Blocking NMDA receptor signaling does not decrease hormonal counterregulation to hypoglycemia in humans. [2008.09]
Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial. [2008.09]
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. [2008.08.15]
A 6-month, open-label study of memantine in patients with frontotemporal dementia. [2008.07]
Tinnitus treatment with memantine. [2008.04]
Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. [2008.04]
Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. [2008.03]
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. [2008.03]
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. [2008.02]
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. [2008.02]
The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. [2008]
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. [2007.12]
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. [2007.09.12]
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. [2007.07]
Pilot trial of memantine in the treatment of posttraumatic stress disorder. [2007.06]
Effects of NMDA receptor antagonist memantine on mismatch negativity. [2007.05.30]
A pilot double-blind treatment trial of memantine for alcohol dependence. [2007.05]
The after-effect of human theta burst stimulation is NMDA receptor dependent. [2007.05]
A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). [2007.05]
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. [2007.04]
Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. [2007.04]
A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. [2007.04]
Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. [2007.03]
Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. [2007.03]
Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency? [2007.03]
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. [2007.03]
Congenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentin. [2007.02]
Treatments to enhance recovery from the vegetative and minimally conscious states: ethical issues surrounding efficacy studies. [2007.02]
Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. [2007.01]
Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study. [2006.12]
Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. [2006.10]
Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. [2006.10]
A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. [2006.08]
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. [2006.08]
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. [2006.07.11]
Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain. [2006.06]
A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. [2006.05]
Memantine for dementia. [2006.04.19]
[Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial] [2006.04]
Effects of pharmacologically induced changes in NMDA receptor activity on human timing and sensorimotor performance. [2006.02.16]
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. [2006.01]
A double-blind, placebo-controlled study of memantine in the treatment of major depression. [2006.01]
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. [2005.10]
The effects of dopamine agonists on prepulse inhibition in healthy men depend on baseline PPI values. [2005.10]
An evaluation of the reinforcing effects of memantine in cocaine-dependent humans. [2005.08.01]
Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy. [2005.08]
Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. [2005.06]
The NMDA antagonist memantine affects training induced motor cortex plasticity -- a study using transcranial magnetic stimulation [ISRCTN65784760]. [2005.05.12]
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. [2005.04]
Other research related to Amantadine
Amantadine-resistant influenza A viruses isolated in South Korea from 2003 to 2009. [2009.11]
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients. [2009.08.15]
Nonimmunologic graft failure after Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) for presumed amantadine-induced corneal edema. [2009.07]
Plasma amantadine concentrations in patients with Parkinson's disease. [2009.06]
Syndrome of inappropriate antidiuretic hormone secretion possibly associated with amantadine therapy in Parkinson disease. [2009.05]
Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. [2009.05]
Obstructive acute renal failure related to amantadine intoxication. [2009.03]
Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. [2009.02]
Status epilepticus in a pediatric patient with amantadine overdose. [2009.02]
Corneal endothelial dysfunction associated with amantadine toxicity. [2008.12]
Modeling amantadine treatment of influenza A virus in vitro. [2008.09.21]
Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. [2008.09]
Cardiotoxicity after massive amantadine overdose. [2008.09]
|
